Cargando…

Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6

INTRODUCTION: Multipotent stromal cells (MSCs) are currently in clinical trials for a number of inflammatory diseases. Recent studies have demonstrated the ability of MSCs to attenuate inflammation in rodent models of acute lung injury (ALI) suggesting that MSCs may also be beneficial in treating AL...

Descripción completa

Detalles Bibliográficos
Autores principales: Danchuk, Svitlana, Ylostalo, Joni H, Hossain, Fokhrul, Sorge, Randy, Ramsey, Austin, Bonvillain, Ryan W, Lasky, Joseph A, Bunnell, Bruce A, Welsh, David A, Prockop, Darwin J, Sullivan, Deborah E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218818/
https://www.ncbi.nlm.nih.gov/pubmed/21569482
http://dx.doi.org/10.1186/scrt68
_version_ 1782216734594301952
author Danchuk, Svitlana
Ylostalo, Joni H
Hossain, Fokhrul
Sorge, Randy
Ramsey, Austin
Bonvillain, Ryan W
Lasky, Joseph A
Bunnell, Bruce A
Welsh, David A
Prockop, Darwin J
Sullivan, Deborah E
author_facet Danchuk, Svitlana
Ylostalo, Joni H
Hossain, Fokhrul
Sorge, Randy
Ramsey, Austin
Bonvillain, Ryan W
Lasky, Joseph A
Bunnell, Bruce A
Welsh, David A
Prockop, Darwin J
Sullivan, Deborah E
author_sort Danchuk, Svitlana
collection PubMed
description INTRODUCTION: Multipotent stromal cells (MSCs) are currently in clinical trials for a number of inflammatory diseases. Recent studies have demonstrated the ability of MSCs to attenuate inflammation in rodent models of acute lung injury (ALI) suggesting that MSCs may also be beneficial in treating ALI. METHODS: To better understand how human MSCs (hMSCs) may act in ALI, the lungs of immunocompetent mice were exposed to lipopolysaccharide (LPS) and four hours later bone marrow derived hMSCs were delivered by oropharyngeal aspiration (OA). The effect of hMSCs on lung injury was assessed by measuring the lung wet/dry weight ratio and total protein in bronchoalveolar lavage (BAL) fluid 24 or 48 h after LPS. BAL fluid was also analyzed for the presence of inflammatory cells and cytokine expression by multiplex immunoassay. Microarray analysis of total RNA isolated from treated and untreated lungs was performed to elucidate the mechanism(s) involved in hMSC modulation of lung inflammation. RESULTS: Administration of hMSCs significantly reduced the expression of pro-inflammatory cytokines, neutrophil counts and total protein in bronchoalveolar lavage. There was a concomitant reduction in pulmonary edema. The anti-inflammatory effects of hMSCs were not dependent on localization to the lung, as intraperitoneal administration of hMSCs also attenuated LPS-induced inflammation in the lung. Microarray analysis revealed significant induction of tumor necrosis factor (TNF)-α-induced protein 6 (TNFAIP6/TSG-6) expression by hMSCs 12 h after OA delivery to LPS-exposed lungs. Knockdown of TSG-6 expression in hMSCs by RNA interference abrogated most of their anti-inflammatory effects. In addition, intra-pulmonary delivery of recombinant human TSG-6 reduced LPS-induced inflammation in the lung. CONCLUSIONS: These results show that hMSCs recapitulate the observed beneficial effects of rodent MSCs in animal models of ALI and suggest that the anti-inflammatory properties of hMSCs in the lung are explained, at least in part, by activation of hMSCs to secrete TSG-6.
format Online
Article
Text
id pubmed-3218818
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32188182011-11-18 Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6 Danchuk, Svitlana Ylostalo, Joni H Hossain, Fokhrul Sorge, Randy Ramsey, Austin Bonvillain, Ryan W Lasky, Joseph A Bunnell, Bruce A Welsh, David A Prockop, Darwin J Sullivan, Deborah E Stem Cell Res Ther Research INTRODUCTION: Multipotent stromal cells (MSCs) are currently in clinical trials for a number of inflammatory diseases. Recent studies have demonstrated the ability of MSCs to attenuate inflammation in rodent models of acute lung injury (ALI) suggesting that MSCs may also be beneficial in treating ALI. METHODS: To better understand how human MSCs (hMSCs) may act in ALI, the lungs of immunocompetent mice were exposed to lipopolysaccharide (LPS) and four hours later bone marrow derived hMSCs were delivered by oropharyngeal aspiration (OA). The effect of hMSCs on lung injury was assessed by measuring the lung wet/dry weight ratio and total protein in bronchoalveolar lavage (BAL) fluid 24 or 48 h after LPS. BAL fluid was also analyzed for the presence of inflammatory cells and cytokine expression by multiplex immunoassay. Microarray analysis of total RNA isolated from treated and untreated lungs was performed to elucidate the mechanism(s) involved in hMSC modulation of lung inflammation. RESULTS: Administration of hMSCs significantly reduced the expression of pro-inflammatory cytokines, neutrophil counts and total protein in bronchoalveolar lavage. There was a concomitant reduction in pulmonary edema. The anti-inflammatory effects of hMSCs were not dependent on localization to the lung, as intraperitoneal administration of hMSCs also attenuated LPS-induced inflammation in the lung. Microarray analysis revealed significant induction of tumor necrosis factor (TNF)-α-induced protein 6 (TNFAIP6/TSG-6) expression by hMSCs 12 h after OA delivery to LPS-exposed lungs. Knockdown of TSG-6 expression in hMSCs by RNA interference abrogated most of their anti-inflammatory effects. In addition, intra-pulmonary delivery of recombinant human TSG-6 reduced LPS-induced inflammation in the lung. CONCLUSIONS: These results show that hMSCs recapitulate the observed beneficial effects of rodent MSCs in animal models of ALI and suggest that the anti-inflammatory properties of hMSCs in the lung are explained, at least in part, by activation of hMSCs to secrete TSG-6. BioMed Central 2011-05-13 /pmc/articles/PMC3218818/ /pubmed/21569482 http://dx.doi.org/10.1186/scrt68 Text en Copyright ©2011 Danchuk et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Danchuk, Svitlana
Ylostalo, Joni H
Hossain, Fokhrul
Sorge, Randy
Ramsey, Austin
Bonvillain, Ryan W
Lasky, Joseph A
Bunnell, Bruce A
Welsh, David A
Prockop, Darwin J
Sullivan, Deborah E
Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6
title Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6
title_full Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6
title_fullStr Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6
title_full_unstemmed Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6
title_short Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6
title_sort human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218818/
https://www.ncbi.nlm.nih.gov/pubmed/21569482
http://dx.doi.org/10.1186/scrt68
work_keys_str_mv AT danchuksvitlana humanmultipotentstromalcellsattenuatelipopolysaccharideinducedacutelunginjuryinmiceviasecretionoftumornecrosisfactorainducedprotein6
AT ylostalojonih humanmultipotentstromalcellsattenuatelipopolysaccharideinducedacutelunginjuryinmiceviasecretionoftumornecrosisfactorainducedprotein6
AT hossainfokhrul humanmultipotentstromalcellsattenuatelipopolysaccharideinducedacutelunginjuryinmiceviasecretionoftumornecrosisfactorainducedprotein6
AT sorgerandy humanmultipotentstromalcellsattenuatelipopolysaccharideinducedacutelunginjuryinmiceviasecretionoftumornecrosisfactorainducedprotein6
AT ramseyaustin humanmultipotentstromalcellsattenuatelipopolysaccharideinducedacutelunginjuryinmiceviasecretionoftumornecrosisfactorainducedprotein6
AT bonvillainryanw humanmultipotentstromalcellsattenuatelipopolysaccharideinducedacutelunginjuryinmiceviasecretionoftumornecrosisfactorainducedprotein6
AT laskyjosepha humanmultipotentstromalcellsattenuatelipopolysaccharideinducedacutelunginjuryinmiceviasecretionoftumornecrosisfactorainducedprotein6
AT bunnellbrucea humanmultipotentstromalcellsattenuatelipopolysaccharideinducedacutelunginjuryinmiceviasecretionoftumornecrosisfactorainducedprotein6
AT welshdavida humanmultipotentstromalcellsattenuatelipopolysaccharideinducedacutelunginjuryinmiceviasecretionoftumornecrosisfactorainducedprotein6
AT prockopdarwinj humanmultipotentstromalcellsattenuatelipopolysaccharideinducedacutelunginjuryinmiceviasecretionoftumornecrosisfactorainducedprotein6
AT sullivandeborahe humanmultipotentstromalcellsattenuatelipopolysaccharideinducedacutelunginjuryinmiceviasecretionoftumornecrosisfactorainducedprotein6